ArticlePloS one2025
Dissecting the inhibitory activity of Burkholderia orbicola against Gram-positive and - negative multidrug-resistant bacteria.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The genus Burkholderia is currently recognized for producing several antimicrobial compounds with potential applications in developing novel treatments for infectious diseases, including those caused by multidrug-resistant (MDR) bacteria. This study aimed to investigate the ability of Burkholderia orbicola TAtl-371T and CACua-24 to inhibit the growth of MDR human pathogens and to analyze the chemical composition of active extracts from cultures of these strains to identify putative compounds associated with their activity. The double-layer agar technique was used to evaluate the antimicrobial activity of B. orbicola strains. Sequential solvent extraction with hexane, dichloromethane, ethyl acetate, and methanol was conducted on B. orbicola cultures, and the active extract was analyzed by bioautography and fractionated using preparative thin-layer chromatography. Putative antimicrobials in the active fraction were identified through 1H, 13C NMR, and mass spectrometry. B. orbicola strains inhibited several MDR strains of Acinetobacter baumannii, Klebsiella pneumoniae, Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus on double-layer agar probes, displaying inhibition halos ranging from 5 to 41 mm. The hexane extract showed the best inhibitory activity against MDR strains, except for P. aeruginosa strains. Analysis through thin-layer chromatography and bioautography revealed a tailing spot with antimicrobial activity. The spectroscopic analysis of this tailing spot revealed the presence of the siderophore fragin. This fragin-containing fraction inhibited the MDR A. baumannii (1024 µg/mL), K. pneumoniae 903137 (128 µg/mL), E. coli (256 µg/mL), and S. aureus (128 µg/mL), but no effect was observed against P. aeruginosa. This fraction also inhibited yeasts of the species Candida albicans and Nakaseomyces glabratus, suggesting an antimicrobial spectrum that extends beyond MDR bacteria. The genomic sequence analysis of strains TAtl-371T and CACua-24 revealed a cluster of 7 genes, resulting in the same organization and over 99% similarity to the fragin genes reported for Burkholderia cenocepacia H111. This study highlights the potential of B. orbicola to produce fragin and its potential activity against MDR bacteria that affect human health worldwide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.